sage-324
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 31, 2020 (NCT04305275)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Gamma-amino-N-butyrate transaminasePOSITIVE ALLOSTERIC MODULATOR
ABAT positive allosteric modulator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05366751 | Phase 2 | Jun 13, 2022 | Sage Therapeutics |
| NCT05173012 | Phase 2 | Jan 24, 2022 | Biogen, Sage Therapeutics |
| NCT04305275 | Phase 2 | Mar 31, 2020 | Sage Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sage Therapeutics | For profit | 3 | 3 | 1 | 2020 |
| Biogen | For profit | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1